Contribution to the Literature: In the EMPHASIS-HF trial, eplerenone when added to optimal medical therapy results in significant improvements. Safety and Efficacy of Eplerenone in Patients at High Risk for Hyperkalemia and/or Worsening Renal Function: Analyses of the EMPHASIS-HF Study Subgroups. comparison trials and differences in clinical trial populations. Based on the RALES, EPHESUS, and EMPHASIS-HF trial results, we recommend the addition of.
|Published:||4 April 2016|
|PDF File Size:||36.16 Mb|
|ePub File Size:||17.34 Mb|
The interaction between the time from the qualifying CVH to randomization and the primary outcome of CV death or hospitalization for HF HHFas well as other secondary outcomes, was emphasis hf trial in Cox survival models. The median time of study drug initiation from qualifying CVH was 42 days.
The adverse effects of eplerenone were also emphasis hf trial by the time from the qualifying CVH. Conclusion Eplerenone is safe, improves survival, and may prevent re-admission when initiated soon after a hospitalization for HF or acute coronary syndromes in patients with systolic HF and mild symptoms.
In the current study, we investigated if the clinical response to a mineralocorticoid receptor antagonist in mildly emphasis hf trial HF patients varied by abdominal obesity.
The potential statistical interaction between the treatment and WC was assessed emphasis hf trial the primary endpoint of death from cardiovascular causes or hospitalization for HF and other secondary endpoints. Over a median follow-up of 21 months, a significant benefit of eplerenone for the primary outcome was noted in both normal [hazard ratio HR 0.
Commenting on the results study presenter Karl Swedberg, from the University of Gothenburg, Sweden, said, "This latest analysis makes an even stronger case for the use of eplerenone in patients with mild heart failure because in emphasis hf trial to reducing mortality it also reduces the incidence of AF.
EMPHASIS-HF TRIAL -
AF is a condition which both increases morbidity and complicates the care of patients with heart failure. Absolute rate reductions were The adverse effects of eplerenone were also unaffected by the time from the qualifying CVH. Eplerenone is safe, improves survival, and may prevent re-admission when initiated soon after a hospitalization for HF or acute coronary emphasis hf trial in patients with systolic HF and mild symptoms.